Table 2 XPD Asp312Asn and Lys751Gln polymorphisms and risk of cutaneous malignant melanoma in the overall analysis and by age, presence of dysplastic naevi or tanning ability

From: XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk

 

XPD 312

XPD 751

 

Genotype

Case

Control

ORa

(95% CI)a

Genotype

Case

Control

ORa

(95% CI)a

Overall analysis

          
 

Asp/Asp (G/G)

52

59

1.0

Ref.

1.5

Lys/Lys (A/A)

58

59

1.0

Ref.

(0.8–2.1)

 

Asp/Asn (G/A) Asn/Asn (A/A)

112

113

 

(0.9-2.5)

Lys/Gln (A/C) Gln/Gln (C/C)

118

118

1.3

 

By age (years)

 17–49

Asp/Asp (G/G)

31

28

1.0

Ref.

(0.4-1.5)

Lys/Lys (A/A)

34

30

1.0

Ref.

(0.4–1.5)

 17–49

Asp/Asn (G/A) Asn/Asn (A/A)

49

74

0.7

 

Lys/Gln (A/C) Gln/Gln (C/C)

51

75

0.7

 

 50–77

Asp/Asp (G/G)

21

31

1.0

Ref.

(1.6–7.3)

Lys/Lys (A/A)

24

29

1.0

Ref.

(1.1–4.9)

 50–77

Asp/Asn (G/A) Asn/Asn (A/A)

63

39

3.4

 

Lys/Gln (A/C) Gln/Gln (C/C)

67

43

2.3

 

Test of heterogeneity of ORsb

    

P=0.004

    

P=0.03

By presence of dysplastic navi c

 No

Asp/Asp (G/G)

12

29

1.0

Ref.

(0.6-3.2)

Lys/Lys (A/A)

9

33

1.0

Ref.

(1.1–6.4)

 No

Asp/Asn (G/A) Asn/Asn (A/A)

40

74

1.4

 

Lys/Gln (A/C) Gln/Gln (C/C)

46

72

2.6

 

 Yes

Asp/Asp (G/G)

23

11

1.0

Ref.

(0.3–2.4)

Lys/Lys (A/A)

26

10

1.0

Ref.

(0.2–1.6)

 Yes

Asp/Asn (G/A) Asn/Asn (A/A)

32

17

0.9

 

Lys/Gln (A/C) Gln/Gln (C/C)

33

19

0.6

 

Test of heterogeneity of ORsb

    

P=0.52

    

P=0.03

By tanning ability

 High/medium

Asp/Asp (G/G)

36

51

1.0

Ref.

(0.7–2.4)

Lys/Lys (A/A)

41

47

1.0

Ref.

(0.6–1.8)

 High/medium

Asp/Asn (G/A) Asn/Asn (A/A)

67

92

1.3

 

Lys/Gln (A/C) Gln/Gln (C/C)

70

99

1.0

 

 Low

Asp/Asp (G/G)

15

8

1.0

Ref.

(0.7-7.0)

Lys/Lys (A/A)

16

11

1.0

Ref.

(1.0-8.8)

 Low

Asp/Asn (G/A) Asn/Asn (A/A)

41

17

2.3

 

Lys/Gln (A/C) Gln/Gln (C/C)

44

15

3.0

 

Test of heterogeneity of ORsb

    

P=0.39

    

P=0.08

  1. aOdds ratios (ORs) and 95% confidence intervals (95% CIs) adjusted for age, gender, dysplastic naevus status, skin colour, tanning ability and eye colour.
  2. bLikelihood-ratio test for interaction with XPD polymorphism.
  3. cSubjects older than 60 years of age were considered as with uncertain dysplastic naevus status.